Shots:

• Aligos to receive an up front to in-license the program directed at 2nd undisclosed NASH target & additional fees for 3rd target, ~$460M in milestones along with royalties. Merck gets the rights to add third target in the cardiometabolic/fibrosis space
• The collaboration will use Aligos’ oligonucleotide platform technology to discover, research, optimize & develop oligonucleotides against NASH target & for one additional target in cardiometabolic/fibrosis space
• Aligos will be responsible for designing, synthesizing & evaluating the oligonucleotide products & delivering optimized lead molecules. Merck will lead the research, clinical development & commercialization

Ref: Globe Newswire | Image: Merck